Abstract
The aims of study– a development of biochemical algorithms of early diagnostic of severity of CHF in patients with DM and IHD and analyze interrelationships between plasma redox-potential, as a marker of progressive of tissues metabolic remodeling and cardiac hypertrophy and markers of progressive of DM, neurohumoral markers of severity of CHF, and frequency of heart rhythm disturbances.Materials and methods.172 patients, male / female (45–65 years), with diagnosis of DM (metabolic decompensation of carbohydrate metabolism, HbА1c – 7.4 ± 1.9 %) during 3–15 years, accompanied with IHD and symptoms of CHF I–IV NYHA functional class (FC). The first point of investigation was examined markers of DM progression HbА1c, changes in FC of HCHF and evidenced prognostic neurohumoral markers of myocardial dysfunction NT-proBNP, and as a second (surrogate) point – changes in redox-potential NAD / NADH and total pool of pyridine nucleotides.Results.Mean NYHA FC CHF in cohort of DM patients and IHD was 2.4 ± 1.2, mean point of CHF estimated by scale of symptoms of CHF was 6.7 ± 0.6, mean distance in 6-minute test was 212 ± 26 m, concentration of neurohumoral markers of myocardial dysfunction NT-proBNP 178 ± 26 fmol / l at the level of HbA1c = 7.8 ± 1.0 %, mean redox-potential of plasma, НАД / НАДН, 0.71 ± 0.06 and total pool of pyridine nucleotide 15.1 ± 1.2 μmol / mg protein of plasma. For the first time was shown that changes in redox-potential and sum of pyridine nucleotide coupled with severity of CHF (FC of CHF), eliminated the correlation between NAD / NADH and HbA1c (r = –0.79, p<0.001), and NTproBNP (r = –0.73; р <0.001), and increasing of tumor necrosis factor alpha (TNF-α, r = –0.73; р <0.001). Simultaneously maintenance decreasing of NAD / NADH and sum of pyridine nucleotide in plasma of patients with DM and IHD coupled with increasing of daily mean values of paired supraventricular and ventricular extrasystoles.Conclusions.In patients with DM and CHF with left ventricular dysfunction the decreasing of redox-potential level in plasma could be recommended as a markers of increasing of metabolic remodeling and progression of cardiac hypertrophy.
Highlights
Цель исследования – разработать биохимический алгоритм ранней диагностики для оценки степени тяжести хронической сердечной недостаточности (ХСН) у больных сахарным диабетом 2-го типа (СД 2) и ишемической болезнью сердца (ИБС) и про вести анализ взаимосвязи между уровнем редокс-потенциала плазмы как маркера нарастания метаболического ремоделирования тканей и гипертрофии миокарда с показателями прогрессирования СД 2 и нейрогормональным маркером прогноза ХСН, а также частотой развития нарушений ритма сердца
For the first time was shown that changes in redox-potential and sum of pyridine nucleotide coupled with severity of CHF (FC of CHF), eliminated the correlation between NAD / NADH and HbA1c (r = –0.79, p
Simulta neously maintenance decreasing of NAD / NADH and sum of pyridine nucleotide in plasma of patients with DM and IHD coupled with in creasing of daily mean values of paired supraventricular and ventricular extrasystoles
Summary
Цель исследования – разработать биохимический алгоритм ранней диагностики для оценки степени тяжести хронической сердечной недостаточности (ХСН) у больных сахарным диабетом 2-го типа (СД 2) и ишемической болезнью сердца (ИБС) и про вести анализ взаимосвязи между уровнем редокс-потенциала плазмы как маркера нарастания метаболического ремоделирования тканей и гипертрофии миокарда с показателями прогрессирования СД 2 и нейрогормональным маркером прогноза ХСН, а также частотой развития нарушений ритма сердца. Результаты Средний ФК ХСН по NYHA в исследуемой когорте больных СД 2 и ИБС составил 2,4 ± 1,2, средний балл по шкале оценки клинического состояния (ШОКС) – 6,7 ± 0,6, среднее проходимое расстояние в тесте 6-минутной ходьбы – 212 ± 26 м, концентрация нейрогормонального маркера миокардиальной дисфункции NT-proBNP в крови 178 ± 26 фмоль / л при HbA1c = 7,8 ± 1,0 %, средний уровень редокс-потенциала плазмы 0,71 ± 0,06 при сумме пиридиновых нуклеотидов 15,1 ± 1,2 мкмоль / мг плазмы (p
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
